Tecvayli (teclistamab-cqyv)
Named-patient access overview. Tecvayli is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
About Tecvayli
Tecvayli (teclistamab-cqyv) is a BCMA x CD3 bispecific T-cell engager developed by Janssen Biotech (a Johnson and Johnson company) in collaboration with Genmab. By simultaneously binding B-cell maturation antigen (BCMA) on myeloma cells and CD3 on cytotoxic T cells, it brings the patient's own T cells into direct contact with the tumour to drive immune-mediated killing.
Tecvayli received accelerated FDA approval in October 2022 for the treatment of adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. It is administered as a subcutaneous (SC) injection and requires a step-up dosing regimen during initiation to mitigate the risk of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
Because of the boxed warnings for CRS and neurologic toxicity, initiation and step-up doses must be administered in a setting equipped for inpatient observation and rapid intervention. Tecvayli is distributed in the US under a Risk Evaluation and Mitigation Strategy (REMS) programme. International access via Named Patient Program or personal-import pathways is coordinated by Reserve Meds for patients in markets where Tecvayli is not yet locally registered.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Tecvayli
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Tecvayli for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Tecvayli is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
Reserve Meds publishes a detailed country deep-dive for Tecvayli in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Start a request for Tecvayli
Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.
Reserve Meds coordinates Tecvayli through Johnson and Johnson portfolio overview for the full cross-border catalog.
Frequently asked questions
How can I get Tecvayli if it is not approved or available in my country?
Reserve Meds coordinates US-sourced Tecvayli for patients through a physician-led, named-patient cross-border pathway. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for your country and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Tecvayli through named-patient or compassionate-use import?
Yes. Named-patient access (also called compassionate use or personal import) is the core route Reserve Meds operates for Tecvayli. Eligibility and paperwork depend on the regulator in your country, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Tecvayli through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Tecvayli to a patient?
Reserve Meds sources Tecvayli from a DSCSA-compliant US specialty supplier with full traceability and coordinates delivery to your treating physician or hospital pharmacy, with appropriate handling for the product.
How long does it take, and what does Tecvayli cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Tecvayli?
Submit a 60-second intake through the Reserve Meds patient portal, or message the concierge team on WhatsApp. A named coordinator follows up within 24 hours.